ATNM stock forecast, quote, news & analysis
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells... Show more
Why Actinium Pharmaceuticals (ATNM) Stock Is Up +32% in the Last 30 Days
Key Takeaways
- ATNM shares rose roughly +32% over the trailing 30 days, climbing from about $1.08 to $1.43.
- The rally was driven primarily by first-in-human Phase 1 data for ATNM-400 in prostate cancer presented at EANM 2026, alongside supportive preclinical pan-tumor results.
- Over the trailing quarter, the stock has advanced roughly +79% from around $0.80 in early August.
- Wall Street analysts reiterated Buy ratings with price targets ranging from $3.00 to $5.00 following the data readout.
- Additional catalysts include the ASH 2026 Actimab-A abstract and the NYSE American compliance-plan extension through November 2027.
- For deeper context on valuation and upcoming catalysts, explore Actinium Pharmaceuticals' Price Targets, Earnings, and Forecast pages.
- Investors tracking momentum and AI-driven strategies can also explore Trending AI Robots for additional market insight.
Actinium Pharmaceuticals (ATNM) Company Overview and Market Position
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies, or radioconjugates, designed to deliver high-energy alpha-particle radiation from Actinium-225 directly to cancer cells. The company's biology-driven approach aims to maximize tumor-killing efficacy while minimizing damage to healthy tissue.
Its pipeline is organized around three pillars: solid tumor programs led by ATNM-400, a first-in-class HER3-targeted Actinium-225 radiotherapy; Actimab-A, a CD33-targeting candidate being developed as a potential therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) through a Cooperative Research and Development Agreement with the National Cancer Institute; and targeted conditioning agents, including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapies. Investors follow the stock closely because of the company's differentiated non-PSMA approach in radiopharmaceuticals and a patent estate of roughly 250 issued and pending patents worldwide.
Actinium Pharmaceuticals (ATNM) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ATNM advanced approximately +32%, rising from a closing price near $1.08 in early October to $1.43. The move was not linear: the shares surged in mid-October around the EANM 2026 data presentations, pulled back briefly, and then regained ground into early November.
The quarterly picture is even stronger. In early August, ATNM traded near $0.80, and the stock has since climbed roughly +79%. This reflects a sustained repricing as the company delivered multiple clinical and intellectual-property milestones, transitioning from a period of depressed valuations toward renewed investor interest in its radiopharmaceutical pipeline.
What Drove ATNM Stock Price in the Last 30 Days
The dominant catalyst was the presentation of first-in-human data for ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026), held in Vienna in October. The company reported encouraging initial results from its Phase 1 dose-escalation study of ATNM-400 in metastatic castration-resistant prostate cancer, demonstrating a favorable early safety profile, sustained tumor retention, and no dose-limiting toxicities in the initial cohort, with escalation advancing to the next dose level.
Alongside the clinical data, Actinium presented preclinical results showing ATNM-400 activity across lung, colorectal, and ovarian cancer models, reinforcing the program's pan-tumor potential. These readouts drove unusually heavy trading volume and a double-digit intraday move in mid-October. The rally was further supported by analyst activity, with firms reiterating Buy ratings and price targets of $3.00 to $5.00 following the data. In early November, the release of an ASH 2026 abstract on long-term safety results for Actimab-A combined with CLAG-M in relapsed or refractory AML added a second, hematology-focused catalyst to the narrative.
What Drove ATNM Stock Performance Over the Last Quarter
Beyond the October data, the broader three-month advance reflects a step-change in the company's fundamental story. In August, Actinium announced advances across its Actimab-A intellectual-property and manufacturing programs and confirmed that NYSE Regulation had accepted its compliance plan, allowing the stock to remain listed on NYSE American through November 2027. This removed a key overhang for investors.
The company also announced new patent allowances spanning its Actimab-A and Iomab-ACT programs, deepening protection across hematologic and cell-therapy conditioning franchises. Together, these developments signaled progress across both the solid-tumor and hematology pipelines, encouraging a re-rating from the multi-month lows seen in early August as investors repositioned ahead of the clinical milestones expected from the fourth quarter of 2026 and into 2027.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader platform that operates hundreds of bots across thousands of tickers. Rather than listing every available strategy, the section highlights the top-performing and most relevant robots, giving traders a focused view of currently active approaches. Each bot differs in its strategy, trading timeframe, and performance metrics, so the page serves as a starting point for identifying automated strategies that align with individual goals and risk tolerance. For investors seeking data-driven, systematic ways to monitor momentum and market conditions, exploring the Trending AI Robots section can offer a useful complement to traditional analysis.
ATNM Stock Forecast Drivers: What Investors Should Watch Next
Several catalysts could shape ATNM's trajectory in the months ahead. First, the ASH 2026 Annual Meeting in December will provide a fuller view of the Actimab-A long-term safety and tolerability data, with the company advancing the program toward a Phase 2/3 trial in AML. Second, continued dose-escalation updates from the ATNM-400 Phase 1 study will be closely watched as the company works toward establishing a recommended Phase 2 dose.
Investors should also monitor the company's progress against its NYSE American compliance plan, ongoing patent activity, and any additional preclinical or partnership updates. As a clinical-stage company with limited revenue, financing and cash runway remain important considerations, and any changes in the broader radiopharmaceutical sector's sentiment or regulatory environment could influence the stock. These are areas to watch rather than guarantees of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATNM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ATNM turned positive on November 10, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATNM as a result. In 66 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 168 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology